totally unaccceptable there is enough sensitivity about even senior doctors doing it, even when we have consulted the patient/family PAs have no business doing this

Please share Respiratory Futures Love Your Lungs INSPIREresp PRISM_SW RSM Respiratory Section RespTRACT NWCORR TERRANE Collaborative Nick Lane

Just out 🔥🔥 Hydrocortisone in severe community acquired pneumonia - results from REMAP-CAP 7 day fixed dose hydrocortisone - Stopped for futility 15% mortality with HC vs 9.8% with standard care. Unlikely that hydrocortisone substantially reduce mortality in CAP.

We did it! Absolutely thrilled to share the results of the ASPEN trial published today in NEJM Brensocatib(10mg and 25mg vs placebo) reduced exacerbations over 52 weeks and slowed lung function decline A new treatment for bronchiectasis patients nej.md/4lBHwUr

Varenicline, combined with behavioral counseling, increased vaping abstinence in youth(16-24) who vape nicotine and do not regularly smoke tobacco. jamanetwork.com/journals/jama/…

ERJ: A single dose of lunsekimig, a bispecific NANOBODY molecule that blocks TSLP and IL-13, was well tolerated, suppressed type 2 inflammation and improved lung function in participants with mild-to-moderate asthma bit.ly/3PTcmJT

Rademikibart Treatment for Moderate-to-Severe Uncontrolled Asthma: A Phase 2B Randomized Clinical Trial Treatment with rademikibart led to rapid (1 week), lasting improvement in lung function in patients with eosinophilic asthma 🔓 Open Access 🔗bit.ly/3GGwAoE

📢 Calling all respiratory & infectious disease clinicians: Have a patient with chronic pulmonary aspergillosis (CPA) starting antifungal therapy? They may be eligible for the INCAS Trial, testing interferon-gamma as an adjunct treatment. 🧪 Learn more: ...

✅ e-Lung is robustly validated in the #INBUILD study to identify progressive pulmonary fibrosis accurately and sensitively ✅ e-Lung helps to identify patients at risk of progressive pulmonary fibrosis We hope to see you in San Francisco! 🌉 Peter George American Thoracic Society (ATS)

Presented at #ATS2025: In the FIBRONEER-IPF phase 3 trial, nerandomilast slowed disease progression in patients with idiopathic pulmonary fibrosis as compared with placebo. Full trial results: nej.md/4mgWcIU American Thoracic Society (ATS)

The goal of this doctor is to sell you supplements like Himalayan Tartary Buckwheat Sprout Powder #QuackHyman

Faecal calprotectin is a validated biomarkers of this in sepsis patients compared days 1 and 3 nature.com/articles/s4159…

🆕 Nature study on #lungcancer in never-smokers challenges long-held assumptions. ✅ Air pollution linked to key mutations ✅ EGFR most common in East Asia ❌ Secondhand smoke not a major factor - minimal genomic impact 68% of our EGFR+ UK members (2024 data) are never-smokers

1/11 Our study on subclonal immune evasion in non-small cell lung cancer has just been published in Cancer Cell cell.com/cancer-cell/fu…

1/ Now the embargo has lifted, I’ve had time to read the The Leng review in full. While some celebrate minor cosmetic wins, I see the formal entrenchment of a parallel, underqualified medical workforce — built without medical training.

This is awful 😢

Viruses cause most asthma exacerbations Hugo Farne 🫁 bit.ly/ERSM108

Effects of Dupilumab on small airways from VESTIGE RCT : Improved small airways function with Dupi due to direct effect on ASM (IL4/13 but not IL5 expression) and dissolution of mucus plugs jacionline.org/article/S0091-…